A carregar...
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
Immunotherapy with checkpoint inhibitors, such as antibodies blocking the programmed cell-death receptor-1 (PD-1), has resulted in remarkable responses in patients having traditionally refractory cancers. Although response to PD-1 inhibitors correlates with PD-1 ligand (PD-L1 or PD-L2) expression, P...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5384346/ https://ncbi.nlm.nih.gov/pubmed/28405512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1284719 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|